AD182 / Apnimed - LARVOL DELTA

Apnimed Achieves Meaningful Results in Proof-of-Concept Crossover Study With Oral Therapeutic Candidates AD504 and AD182 for the Treatment of Obstructive Sleep Apnea (Businesswire) - P2, N=15; NCT04645524; Sponsor: Apnimed; "Apnimed...announced positive topline results from a proof-of-concept randomized, controlled, double-blind, single-dose, three-period crossover study (protocol APX-001) in patients with OSA evaluating AD504 and AD182...AD504 showed a strong trend in reduction of AHI from placebo (from 18.2[11.8-31.3] events/hour to 7.4[5.4-16.1] events/hour, p=0.06) and a significant reduction in HB from placebo (from 48.2[31.2-79.6] to 18.7[14.9-43.5] %min/hour, p<0.001). AD182 also demonstrated a trend towards reduction in HB relative to placebo."

P2 data • CNS Disorders • Obstructive Sleep Apnea • Sleep Disorder

Crossover Trial of AD182 and AD504 in Obstructive Sleep Apnea (clinicaltrials.gov) - P2; N=15; Completed; Sponsor: Apnimed; Recruiting ➔ Completed

Clinical • Trial completion • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Disorder